Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9IDUH)

Drug Name
TRX518 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM9IDUH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Activation-inducible TNFR family receptor (TNFRSF18)
Drug Name Drug ID Indication ICD 11 Highest Status REF
INCAGN01876 DMNUXKA Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
INCAGN1876 DM8XN4A Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
TRX-518 DMQS5DY Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
MK-4166 DML5V76 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
REGN6569 DM0ZMNI Squamous head and neck cell carcinom 2D60.0 Phase 1 [7]
AMG 228 DMLQJ5P Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
ASP1951 DMX4PWV Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation-inducible TNFR family receptor (TNFRSF18) TTG6LA7 TNR18_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT02628574) Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Leap Therapeutics.
3 Clinical pipeline report, company report or official report of Agenus.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
6 Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
7 Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
8 Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.
9 ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.